ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AZN AstraZeneca PLC

54.17
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
AstraZeneca PLC NYSE:AZN NYSE Depository Receipt
  Price Change % Change Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 54.17 0 01:00:00

AstraZeneca Cell Lung Cancer Treatment Imfinzi Gets FDA Approval

19/02/2018 7:51am

Dow Jones News


AstraZeneca (NYSE:AZN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more AstraZeneca Charts.

By Dimitrios Kontos

 

AstraZeneca PLC (AZN.LN) said Monday that Imfinzi has received the approval of the U.S. Food and Drug Administration for the treatment of patients with a form of cell lung cancer.

Imfinzi is the only immunotherapy approved for patients with Stage 3 non-small cell lung cancer that cannot be removed via surgery, the London-listed pharmaceutical company said.

The approval is based on the study's results, which showed that Imfinzi can help prolong patients' lives, the company said.

The company also said until Imfinzi, patients had no FDA-approved treatment options after chemoradiation therapy.

 

Write to Dimitrios Kontos at dimitrios.kontos@dowjones.com

 

(END) Dow Jones Newswires

February 19, 2018 02:36 ET (07:36 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year AstraZeneca Chart

1 Year AstraZeneca Chart

1 Month AstraZeneca Chart

1 Month AstraZeneca Chart

Your Recent History

Delayed Upgrade Clock